WNX
Wellnex Life Ltd
- Announcements, last 12 months
- 46
- Price sensitive, last 12 months
- 12
- Followed on InvestorPA
- Low (Outside the 20% most-followed companies on InvestorPA)
Latest announcements
Sign in to see all WNX announcements.
Guidance history
| 28 Feb 2025 | Revenue and margin growth expected to continue in 2H FY25 with continued growth of brands in distribution and sales, and expansion of IP licensing arrangements, primarily driven by the international expansion of the Haleon arrangement. The company is targeting a positive EBITDA for H2 FY25. | |
| 10 Feb 2025 | Wellnex Life expects to save approximately $1.4 million in annual costs through the redemption of convertible notes and payment of deferred consideration for the Pain Away acquisition. | |
| 31 Jan 2025 | Wellnex Life reported record sales of $11.94 million in 1H FY25, up 112% compared to the prior corresponding period. This was driven by a 182% increase in brand sales to $8.47 million and a 64% increase in IP Licensing sales to $3.47 million. |
Most followed in Consumer Staples
Follow WNX to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.
Sign in